• Treffer 6 von 12
Zurück zur Trefferliste

An anti-ubiquitin antibody response in transitional cell carcinoma of the urinary bladder

Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-143711
  • Background To use combinatorial epitope mapping ("fingerprinting") of the antibody response to identify targets of the humoral immune response in patients with transitional cell carcinoma (TCC) of the bladder. Methods A combinatorial random peptide library was screened on the circulating pool of immunoglobulins purified from an index patient with a high risk TCC (pTa high grade plus carcinoma in situ) to identify corresponding target antigens. A patient cohort was investigated for antibody titers against ubiquitin. Results WeBackground To use combinatorial epitope mapping ("fingerprinting") of the antibody response to identify targets of the humoral immune response in patients with transitional cell carcinoma (TCC) of the bladder. Methods A combinatorial random peptide library was screened on the circulating pool of immunoglobulins purified from an index patient with a high risk TCC (pTa high grade plus carcinoma in situ) to identify corresponding target antigens. A patient cohort was investigated for antibody titers against ubiquitin. Results We selected, isolated, and validated an immunogenic peptide motif from ubiquitin as a dominant epitope of the humoral response. Patients with TCC had significantly higher antibody titers against ubiquitin than healthy donors (p<0.007), prostate cancer patients (p<0.0007), and all patients without TCC taken together (p<0.0001). Titers from superficial tumors were not significantly different from muscle invasive tumors (p = 0.0929). For antibody response against ubiquitin, sensitivity for detection of TCC was 0.44, specificity 0.96, positive predictive value 0.96 and negative predictive value 0.41. No significant titer changes were observed during the standard BCG induction immunotherapy. Conclusions This is the first report to demonstrate an anti-ubiquitin antibody response in patients with TCC. Although sensitivity of antibody production was low, a high specificity and positive predictive value make ubiquitin an interesting candidate for further diagnostic and possibly immune modulating studies.zeige mehrzeige weniger

Volltext Dateien herunterladen

Metadaten exportieren

Weitere Dienste

Teilen auf Twitter Suche bei Google Scholar Statistik - Anzahl der Zugriffe auf das Dokument
Metadaten
Autor(en): Peter U. Ardelt, Jan Ebbing, Fabian Adams, Cora Reiss, Wadih Arap, Renata Pasqualini, Alexander Bachmann, Ulrich Wetterauer, Hubertus Riedmiller, Burkard Kneitz
URN:urn:nbn:de:bvb:20-opus-143711
Dokumentart:Artikel / Aufsatz in einer Zeitschrift
Institute der Universität:Medizinische Fakultät / Urologische Klinik und Poliklinik
Sprache der Veröffentlichung:Englisch
Titel des übergeordneten Werkes / der Zeitschrift (Englisch):PLoS ONE
Erscheinungsjahr:2015
Band / Jahrgang:10
Heft / Ausgabe:3
Seitenangabe:e0118646
Originalveröffentlichung / Quelle:PLoS ONE 10(3): e0118646 (2015). DOI: 10.1371/journal.pone.0118646
DOI:https://doi.org/10.1371/journal.pone.0118646
Allgemeine fachliche Zuordnung (DDC-Klassifikation):6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Freie Schlagwort(e):Bacillus-Calmette-Guerin; cancer surveillance; immune response; immunotherapy; protein biomarkers; system bcg; tumor cells; ubiquitin
Datum der Freischaltung:01.06.2018
Lizenz (Deutsch):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International